Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequity, Neurology, vol.83, issue.11, pp.1022-1024, 2014. ,
, , 2012.
What's new in multiple sclerosis?, Br J Gen Pract, vol.64, issue.629, pp.612-613, 2014. ,
Histoire naturelle de la sclérose en plaques. /data/revues/07554982/v39i3/S075549820900565X, 2010. ,
, Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group, Lancet Lond Engl, vol.352, issue.9139, pp.1498-1504, 1998.
Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group, Neurology, vol.45, issue.7, pp.1268-1276, 1995. ,
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis, N Engl J Med, vol.354, issue.9, pp.899-910, 2006. ,
Oligodendrocyte regeneration: Its significance in myelin replacement and neuroprotection in multiple sclerosis, Neuropharmacology, vol.110, pp.633-643, 2016. ,
La neuro-inflammation -Dr Jekyll ou Mr Hyde ? médecine/sciences, vol.31, pp.979-988, 2015. ,
Multiple sclerosis, Lancet Lond Engl, vol.372, issue.9648, pp.1502-1517, 2008. ,
URL : https://hal.archives-ouvertes.fr/hal-00996686
Namerow NS, Enns N. Visual evoked responses in patients with multiple sclerosis, J Neurol Neurosurg Psychiatry, vol.17, issue.2, pp.829-833, 1972. ,
doi:The History of Cerebrospinal Fluid Analysis in Multiple Sclerosis: A Great Development over the Last Centuries 14, NUCLEAR MAGNETIC RESONANCE IMAGING OF THE BRAIN IN MULTIPLE SCLEROSIS. The Lancet, vol.1, 2017. ,
, , vol.318, pp.1063-1066
The experimental autoimmune encephalomyelitis (EAE) model of MS: utility for understanding disease pathophysiology and treatment, Handb Clin Neurol, vol.13, issue.3, pp.173-189, 1983. ,
Immunology of multiple sclerosis, Annu Rev Immunol, vol.23, pp.683-747, 2005. ,
Immunité adaptative et physiopathologie de la sclérose en plaques, Rev Médecine Interne, vol.34, issue.8, pp.479-486, 2013. ,
Ocrelizumab and Other CD20+ B-Cell-Depleting Therapies in Multiple Sclerosis, Neurother J Am Soc Exp Neurother, vol.14, issue.4, pp.835-841, 2017. ,
Efficacy of rituximab in refractory RRMS, Mult Scler Houndmills Basingstoke Engl, vol.25, issue.6, pp.828-836, 2019. ,
URL : https://hal.archives-ouvertes.fr/hal-02066062
Immunopathology of multiple sclerosis, Nat Rev Immunol, vol.15, issue.9, pp.545-558, 2015. ,
Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin, Nature, vol.356, issue.6364, pp.63-66, 1992. ,
Physiopathologie de la sclérose en plaques, 2019. ,
Microglial cell cytotoxicity of oligodendrocytes is mediated through nitric oxide, J Immunol Baltim Md, vol.151, issue.4, pp.2132-2141, 1950. ,
Expression of the betachemokine receptors CCR2, CCR3 and CCR5 in multiple sclerosis central nervous system tissue, J Neuroimmunol, vol.108, issue.1-2, pp.192-200, 2000. ,
Demyelination in multiple sclerosis, Handb Clin Neurol, vol.122, pp.89-99, 2014. ,
Le complexe majeur d'histocompatibilité humain (HLA). :13. 28. Hollenbach JA, Oksenberg JR. The Immunogenetics of Multiple Sclerosis: A Comprehensive Review, J Autoimmun, vol.64, pp.13-25, 2015. ,
Fine-mapping the genetic association of the major histocompatibility complex in multiple sclerosis: HLA and non-HLA effects, PLoS Genet ,
, , vol.9, p.1003926
From genes to function: the next challenge to understanding multiple sclerosis, Nat Rev Immunol, vol.9, issue.6, pp.408-417, 2009. ,
Epstein-Barr virus and multiple sclerosis, Epidemiol Camb Mass, vol.11, issue.2, pp.220-224, 2000. ,
Anti-Epstein-Barr virus antibodies as serological markers of multiple sclerosis: a prospective study among United States military personnel, Mult Scler Houndmills Basingstoke Engl, vol.17, issue.10, pp.1185-1193, 2011. ,
Molecular mimicry in multiple sclerosis, Autoimmunity, vol.39, issue.1, pp.3-8, 2006. ,
Smoking is a risk factor for multiple sclerosis: a metanalysis, Mult Scler Houndmills Basingstoke Engl, vol.13, issue.5, pp.610-615, 2007. ,
Smoking as a risk factor for multiple sclerosis, Mult Scler Houndmills Basingstoke Engl, vol.19, issue.8, pp.1022-1027, 2013. ,
Vitamine D et auto-immunité. /data/revues/07554982/v42i10/S0755498213006817, 2013. ,
Vitamin D and multiple sclerosis: An update, Mult Scler Relat Disord, vol.14, pp.35-45, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01501453
Role of intestinal microbiota in the development of multiple sclerosis, Neurol Barc Spain, vol.32, issue.3, pp.169-180, 2017. ,
Increasing incidence of multiple sclerosis among women in Lorraine, Eastern France. Mult Scler Houndmills Basingstoke Engl, vol.13, pp.962-967, 2007. ,
Epidemiology of multiple sclerosis, Rev Neurol ,
URL : https://hal.archives-ouvertes.fr/hal-01255824
, , vol.172, pp.3-13
Defining the clinical course of multiple sclerosis, Neurology, vol.83, issue.3, pp.278-286, 2014. ,
Highly active multiple sclerosis: An update, Mult Scler Relat Disord, vol.30, pp.215-224, 2019. ,
Rebond d'activité inflammatoire et triggers de poussées, POINT SUR, vol.21, p.6, 2018. ,
Recurrence of disease activity during pregnancy after cessation of fingolimod in multiple sclerosis, Mult Scler Houndmills Basingstoke Engl, vol.24, issue.7, pp.991-994, 2018. ,
Dramatic rebounds of MS during pregnancy following fingolimod withdrawal, Neurol Neuroimmunol Neuroinflammation, vol.4, issue.5, p.377, 2017. ,
Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis, Neurology, vol.76, issue.22, pp.1858-1865, 2011. ,
Natalizumab discontinuation and disease restart in pregnancy: a case series, Acta Neurol Scand, vol.131, issue.5, pp.336-340, 2015. ,
Recurrent disease-activity rebound in a patient with multiple sclerosis after natalizumab discontinuations for pregnancy planning, Mult Scler Houndmills Basingstoke Engl, vol.22, issue.11, pp.1506-1508, 2016. ,
Risk of relapse after natalizumab withdrawal: Results from the French TYSEDMUS cohort, Neurol Neuroimmunol Neuroinflammation, vol.3, issue.6, p.297, 2016. ,
Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS), Neurology, vol.33, issue.11, pp.1444-1452, 1983. ,
Sclérose en plaques et grossesse. /data/revues/00353787/01620003/299, 2008. ,
Rate of Pregnancy-Related Relapse in Multiple Sclerosis, N Engl J Med, vol.339, issue.5, pp.285-291, 1998. ,
Fertility in patients with multiple sclerosis: current knowledge and future perspectives, Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol, vol.27, issue.4, pp.231-239, 2006. ,
Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse, Brain J Neurol, vol.127, pp.1353-1360, 2004. ,
URL : https://hal.archives-ouvertes.fr/hal-00427677
Long-term effects of childbirth in MS, J Neurol Neurosurg Psychiatry, vol.81, issue.1, pp.38-41, 2010. ,
Epidural analgesia and cesarean delivery in multiple sclerosis post-partum relapses: the Italian cohort study, BMC Neurol, vol.12, p.165, 2012. ,
Exclusive Breastfeeding and the Effect on Postpartum Multiple Sclerosis Relapses, JAMA Neurol, vol.72, issue.10, pp.1132-1138, 2015. ,
Steroids in multiple sclerosis, J Clin Pharm Ther, vol.19, issue.4, pp.219-222, 1994. ,
COPOUSEP : corticoïdes à forte dose par voie orale versus intraveineuse dans le traitement des poussées de sclérose en plaques : un essai randomisé en double insu : résultats du critère majeur d'efficacité à 1 mois. /data/revues/00353787/v170sS1/S0035378714005566, Clin Exp Immunol, vol.127, issue.1, pp.165-171, 2002. ,
Oral versus intravenous methylprednisolone for the treatment of multiple sclerosis relapses: A meta-analysis of randomized controlled trials, PloS One, vol.12, issue.11, p.188644, 2017. ,
Interferon beta-1a for early multiple sclerosis: CHAMPS trial subgroup analyses, Ann Neurol, vol.51, issue.4, pp.481-490, 2002. ,
Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG), Ann Neurol, vol.39, issue.3, pp.285-294, 1996. ,
Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial, Lancet Neurol, vol.8, issue.11, pp.987-997, 2009. ,
Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group, Neurology, vol.43, issue.4, pp.662-667, 1993. ,
Pegylated interferon ?-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study, Lancet Neurol, vol.13, issue.7, pp.657-665, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-01097451
Neuroprotection with glatiramer acetate: evidence from the PreCISe trial, J Neurol, vol.260, issue.7, pp.1901-1906, 2013. ,
European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group, Ann Neurol, vol.49, issue.3, pp.290-297, 2001. ,
Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis, N Engl J Med, vol.367, issue.12, pp.1098-1107, 2012. ,
Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, N Engl J Med, vol.367, issue.12, pp.1087-1097, 2012. ,
, Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis | NEJM, 2019.
Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet Neurol, vol.13, issue.3, pp.247-256, 2014. ,
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial, Lancet Neurol, vol.13, issue.6, pp.545-556, 2014. ,
Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial, Lancet Neurol, vol.13, issue.3, pp.257-267, 2014. ,
Mitoxantrone in progressive multiple sclerosis: a placebocontrolled, double-blind, randomised, multicentre trial, Lancet Lond Engl, vol.360, issue.9350, pp.2018-2025, 2002. ,
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis, N Engl J Med, vol.376, issue.3, pp.221-234, 2017. ,
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial, Lancet Lond Engl, vol.380, issue.9856, pp.61768-61769, 2012. ,
Natalizumab (Tysabri), Am J Neuroradiol, vol.31, issue.9, pp.1588-1590, 2010. ,
The pathophysiologic role of alpha 4 integrins in vivo, J Clin Invest, vol.94, issue.5, 1994. ,
Medication use in pregnancy: a cross-sectional, multinational web-based study, BMJ Open, vol.4, issue.2, p.4365, 2014. ,
,
, , 2019.
, Académie Natl Médecine Une Inst Dans Son Temps, 2009.
Le passage transplacentaire des médicaments, Thérapie, vol.69, issue.1, pp.3-11, 2014. ,
Le placenta humain : neuf mois d'une intense activité encore méconnue ,
, , vol.1, pp.509-516, 1999.
Pregnancy outcomes in multiple sclerosis following subcutaneous interferon beta-1a therapy, Mult Scler Houndmills Basingstoke Engl, vol.17, issue.4, pp.423-430, 2011. ,
Final results from the Betaseron (interferon ?-1b) Pregnancy Registry: a prospective observational study of birth defects and pregnancy-related adverse events, Release Dimethyl Fumarate and Pregnancy, vol.4, pp.9-14, 2014. ,
, Pregnancy Outcome and Teriflunomide Treatment Exposure for Relapsing Remitting Multiple Sclerosis A 4 year follow up (P1.359) | Neurology, Preclinical Studies and Pregnancy Outcomes from Clinical Trials and Postmarketing Experience, vol.4, pp.93-104, 2015.
Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis, Neurology, vol.82, issue.8, pp.674-680, 2014. ,
Cell adhesion events mediated by ?4 integrins are essential in placental and cardiac development, p.12 ,
Expanding roles for alpha 4 integrin and its ligands in development, Cell Adhes Commun, vol.2, issue.1, pp.27-43, 1994. ,
Integrin function and regulation in development, Int J Dev Biol, vol.44, issue.6, pp.725-731, 2000. ,
Evaluation of pregnancy outcomes from the Tysabri® (natalizumab) pregnancy exposure registry: a global, observational, follow-up study, BMC Neurol, vol.16, issue.1, p.150, 2016. ,
Pregnancy and natalizumab: results of an observational study in 35 accidental pregnancies during natalizumab treatment, Mult Scler Houndmills Basingstoke Engl, vol.17, issue.8, pp.958-963, 2011. ,
Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks, Neurology, vol.90, issue.10, pp.823-831, 2018. ,
Natalizumab use during the third trimester of pregnancy, JAMA Neurol, vol.71, issue.7, pp.891-895, 2014. ,
865 PIANO: A 1000 Patient Prospective Registry of Pregnancy Outcomes in Women With IBD Exposed to Immunomodulators and Biologic Therapy, Gastroenterology, vol.142, issue.5, pp.60561-60568, 2012. ,
Embryo/fetal development in cynomolgus monkeys exposed to natalizumab, an alpha4 integrin inhibitor, Birth Defects Res B Dev Reprod Toxicol, vol.86, issue.2, pp.117-130, 2009. ,
Effects of natalizumab, an alpha4 integrin inhibitor, on the development of Hartley guinea pigs, Birth Defects Res B Dev Reprod Toxicol, vol.86, issue.2, pp.98-107, 2009. ,
Evaluation of pregnancy outcomes from the Tysabri® (natalizumab) pregnancy exposure registry: a global, observational, follow-up study, BMC Neurol, vol.16, issue.1, p.150, 2016. ,
Pregnancy and fetal outcomes following natalizumab exposure in pregnancy. A prospective, controlled observational study, Mult Scler Houndmills Basingstoke Engl, vol.21, issue.2, pp.198-205, 2015. ,
Normal outcome of pregnancy with ongoing treatment with natalizumab, Acta Neurol Scand, vol.129, issue.6, pp.27-29, 2014. ,
Pregnancy and natalizumab: results of an observational study in 35 accidental pregnancies during natalizumab treatment, Mult Scler Houndmills Basingstoke Engl, vol.17, issue.8, pp.958-963, 2011. ,
Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks, Acta Neurol Scand, vol.123, issue.6, pp.823-831, 2011. ,
Natalizumab treatment during pregnancy -effects on the neonatal immune system, Acta Neurol Scand, vol.127, issue.1, pp.1-4, 2013. ,
Natalizumab exposure during pregnancy in multiple sclerosis: a systematic review, J Neurol Sci, vol.396, pp.202-205, 2019. ,
Clinical activity after fingolimod cessation: disease reactivation or rebound?, Eur J Neurol, vol.25, issue.10, pp.1270-1275, 2018. ,
Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients, J Neurol, vol.261, issue.6, pp.1170-1177, 2014. ,
Rebound of disease activity during pregnancy after withdrawal of fingolimod, Eur J Neurol, vol.20, issue.8, pp.109-110, 2013. ,
Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks, Neurology, vol.90, issue.10, pp.832-839, 2018. ,
Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse, Brain J Neurol, vol.127, pp.1353-1360, 2004. ,
URL : https://hal.archives-ouvertes.fr/hal-00427677
The role of the placenta in drug transport and fetal drug exposure, Expert Rev Clin Pharmacol, vol.11, issue.4, pp.373-385, 2018. ,
Reporting birth defects surveillance data 1968-2003, Birt Defects Res A Clin Mol Teratol, vol.79, issue.2, pp.65-186, 2007. ,
Audipog perinatal network. Part 1: principal perinatal health indicators, 2004. ,
, Gynecol Obstet Fertil, vol.36, issue.11, pp.1091-1100, 2008.
Natalizumab use during the third trimester of pregnancy, JAMA Neurol, vol.71, issue.7, pp.891-895, 2014. ,
Neonatal pancytopenia in a child, born after maternal exposure to natalizumab throughout pregnancy, J Gynecol Obstet Hum Reprod, vol.46, issue.3, pp.301-302, 2017. ,
,
, J Gynecol Obstet Biol Reprod, vol.43, issue.10, pp.764-775, 2014.
Dimesse dagli istituti di cura per aborto spontaneo e Indagine rapida sulle donne dimesse per aborto spontaneo, BJOG Int J Obstet Gynaecol, vol.115, issue.2, pp.176-182, 2008. ,
Rôle des intégrines et sélectines dans le développement et les régulations du système hématopoïétique, Hématologie, vol.7, issue.2, pp.99-109, 2001. ,